Navigation Links
How blocking the 'Programmed Death 1' protein may treat or prevent sepsis and severe infection
Date:8/2/2010

Scientists have made an important discovery that could lead to new drugs that reduce the severity of blood infections leading to sepsis. Research presented in the August 2010 issue of Journal of Leukocyte Biology (http://www.jleukbio.org) shows how interfering with the function of the cell membrane protein called "Programmed Death 1" (PD-1) improves survival in a clinically relevant model of severe infection.

"Clinical trials of anti-PD-1 are currently underway in patients with cancer and in patients with hepatitis C," said Richard S. Hotchkiss, M.D., co-study author from the Department of Anesthesiology at Washington University School of Medicine in St. Louis, MO. "It is hoped that blocking PD-1 will lead to enhanced immune function and a resultant improved tumor elimination and viral eradication respectively."

To make this discovery, the researchers studied two groups of mice with a surgically induced severe infection that simulates a ruptured appendix in humans. One group of mice received an inactive antibody while the other group of mice received an antibody that blocked PD-1. The mice that received the PD-1 blocking antibody had a greater survival rate when compared to the mice that received the inactive control antibody. Results show that PD-1 inhibits the ability of the immune system to fight infection by suppressing the function of immune cells. Thus, blocking PD-1 can restore the ability of the host to combat infections, also helping to improve chances for survival.

"This research may lead to a new class of drugs that could treat severe bacterial infections, including those that are becoming increasingly resistant to today's antibiotics," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology, "This study is one of science's many steps to keep pace or a step ahead of the evolutionary progress that these microrganisms are making."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-515-0371
Federation of American Societies for Experimental Biology
Source:Eurekalert

Page: 1

Related biology news :

1. Blocking cancer in its path: New cellular defect discovered
2. Blocking cell movement for cancer, MS treatment
3. Caltech scientists show why anti-HIV antibodies are ineffective at blocking infection
4. Genetically reprogrammed HSV given systemically shrinks distant sarcomas
5. Reprogrammed human blood cells show promise for disease research
6. Study reveals a reprogrammed role for the androgen receptor
7. Study by NTU professors provides important insight into apoptosis or programmed cell death
8. Study finds blood cells can be reprogrammed to act as embryonic stem cells
9. Researchers piggyback to safer reprogrammed stem cells
10. New UGA temperature table may help reduce heat-related deaths of children in closed cars
11. Deaths in the family cause bacteria to flee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
(Date:3/20/2017)... Pa. , March 20, 2017 PMD ... 2.0 personal spirometer and Wellness Management System (WMS), a ... Founded in 2010, PMD Healthcare is a Medical ... with a mission dedicated to creating innovative solutions that ... life. With that intent focus, PMD developed the first ...
(Date:3/7/2017)... -- Brandwatch , the leading social intelligence company, today announces ... to uncover insights to support its reporting, help direct future campaigns, ... leading youth charity will be using Brandwatch Analytics social listening and ... understanding of the topics and issues that are a priority for ... "Until ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... ... March 27, 2017 , ... IsoPlexis Corporation (IsoPlexis), a venture ... and more through a single-cell precision engineering platform, today announced it has received ... in the laboratory of Dr. James Heath at the California Institute of Technology, ...
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... engineer scalable and customizable vascular grafts in JoVE’s Video Journal, the world’s first ... new and improved ways of treating coronary artery disease (CAD). Lam is an ...
(Date:3/24/2017)... 24, 2017 MiMedx Group, Inc. (NASDAQ: MDXG), ... placental tissue allografts and patent-protected processes to develop and ... healthcare, announced today  that it will present at the ... , NY.  Parker H. "Pete" Petit, Chairman and CEO, ... Christopher M. Cashman , EVP and Chief Commercialization Officer, ...
Breaking Biology Technology: